Number of items: 10.
2022
Dwomoh, L. et al.
(2022)
M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease.
Science Signaling, 15(760),
eabm3720.
(doi: 10.1126/scisignal.abm3720)
(PMID:36378750)
2021
Scarpa, M. et al.
(2021)
Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease.
Proceedings of the National Academy of Sciences of the United States of America, 118(50),
e2107389118.
(doi: 10.1073/pnas.2107389118)
(PMID:34893539)
(PMCID:PMC8685681)
Brown, A. J.H. et al.
(2021)
From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease.
Cell, 184(24),
5886-5901.e22.
(doi: 10.1016/j.cell.2021.11.001)
(PMID:34822784)
2020
Bradley, S. J. et al.
(2020)
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.
Nature Chemical Biology, 16(3),
pp. 240-249.
(doi: 10.1038/s41589-019-0453-9)
(PMID:32080630)
Khajehali, E., Bradley, S. , van der Westhuizen, E. T., Molloy, C. , Valant, C., Finlayson, L. , Lindsley, C. W., Sexton, P. M., Tobin, A. B. and Christopoulos, A.
(2020)
Restoring agonist function at a chemogenetically modified M1 muscarinic acetylcholine receptor.
ACS Chemical Neuroscience, 11(24),
pp. 4270-4279.
(doi: 10.1021/acschemneuro.0c00540)
(PMID:33196174)
2019
Thompson, K.J., Khajehali, E., Molloy, C. , Valant, C., Bradley, S.J. , Sexton, P.M., Christopoulos, A. and Tobin, A.B.
(2019)
The In Vitro Characterisation of DREADD Agonist 21, a Novel Ligand for Muscarinic DREADD Receptors.
British Journal of Pharmacology 176(16): 3002-3003. Selected Abstract from Pharmacology 2018, London, UK, 18-20 Dec 2018.
(doi: 10.1111/bph.14681)
Bolognini, D. et al.
(2019)
Chemogenetics defines receptor-mediated functions of short chain free fatty acids.
Nature Chemical Biology, 15(5),
pp. 489-498.
(doi: 10.1038/s41589-019-0270-1)
(PMID:30992568)
2018
Thompson, K. J. et al.
(2018)
DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo.
ACS Pharmacology and Translational Science, 1(1),
pp. 61-72.
(doi: 10.1021/acsptsci.8b00012)
(PMID:30868140)
(PMCID:PMC6407913)
Bradley, S. J. et al.
(2018)
Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes.
Molecular Pharmacology, 93(6),
pp. 645-656.
(doi: 10.1124/mol.118.111872)
(PMID:29695609)
(PMCID:PMC5963591)
2017
Bradley, S. J. et al.
(2017)
M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
Journal of Clinical Investigation, 127(2),
pp. 487-499.
(doi: 10.1172/JCI87526)
(PMID:27991860)
(PMCID:PMC5272187)
This list was generated on Mon Dec 2 04:33:16 2024 GMT.